683 Capital Management, LLC Fate Therapeutics Inc Transaction History

683 Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $9.02 Million - $14.7 Million	-125,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $3.81 Million - $10.1 Million	-100,000 Reduced 44.44%	125,000 $11.4 Million
Q3 2019 Nov 14, 2019	SELL	$15.47 - $22.5 $1.16 Million - $1.69 Million	-75,000 Reduced 25.0%	225,000 $3.49 Million
Q2 2019 Aug 14, 2019	SELL	$15.61 - $20.44 $1.48 Million - $1.94 Million	-95,000 Reduced 24.05%	300,000 $6.09 Million
Q1 2019 May 15, 2019	SELL	$13.15 - $18.71 $131,500 - $187,100	-10,000 Reduced 2.47%	395,000 $6.94 Million
Q4 2018 Feb 14, 2019	SELL	$11.48 - $16.98 $2.81 Million - $4.16 Million	-244,800 Reduced 37.67%	405,000 $5.2 Million
Q3 2018 Nov 14, 2018	SELL	$8.75 - $16.29 $824,346 - $1.53 Million	-94,211 Reduced 12.66%	649,800 $10.6 Million
Q2 2018 Aug 14, 2018	SELL	$9.16 - $13.48 $2.29 Million - $3.37 Million	-249,700 Reduced 25.13%	744,011 $8.44 Million
Q1 2018 May 15, 2018	BUY	$6.3 - $13.77 $881,439 - $1.93 Million	139,911 Added 16.39%	993,711 $9.7 Million
Q4 2017 Feb 14, 2018	BUY	$3.94 - $6.64 $689,500 - $1.16 Million	175,000 Added 25.78%	853,800 $5.22 Million
Q3 2017 Nov 14, 2017	BUY	$2.6 - $4.31 $1.76 Million - $2.93 Million	678,800	678,800 $2.69 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $260M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on 683 Capital Management, LLC with notifications on news.